5 [31] was used to determine the

best-fit model that resulted in the selection of an uncorrelated exponential relaxed molecular clock. The tree was obtained using the Tree Annotator program in BEAST and the evolutionary trees were viewed in FigTree Doxorubicin solubility dmso program 1.3.1. The relationship between predicted protection (r1-value ≥0.3) and changes in aa was analysed using a general linear model (GLM) with binomial error distribution. For this, a binomial variable ‘protected/not protected’ was created based on the estimated r1-values ≥0.3 (protected), which was used as the response variable. Summaries of the aa count differences between the query sequence of the vaccine strain and those of the field viruses were used as independent variables using either entire P1 aa sequence and each of the different viral proteins (VP1-4), alone or in combination. Both variables were analysed independently in a univariate analysis and together in a multivariate analysis. The GLM modelling and analysis of the data was carried out using R [32]. In FMD endemic settings, implementation of the progressive disease control pathway [13] requires vaccines that can protect against both circulating and emerging variants, regular vaccination campaigns, post-vaccination sero-monitoring and biosecurity measures in the form of livestock movement

control. Therefore, selection of appropriate vaccine strains is an important element in implementing vaccination policies for the control click here of FMD. FMD is enzootic in East Africa, with outbreaks reported regularly [15], [33], [34] and [35]. Although the region has two vaccine

producing plants, there is little information available on the protective value of the supplied vaccines. The only report on vaccine strain selection in East Africa [21] was limited to a small selection of Ethiopian vaccines (two) and viruses (five). In addition, Kenya uses historic viruses such as A-KEN-05-1980 (A/K/5/80) and A-KEN-35-1980 (A/K/35/80) for vaccine production [22] and the vaccine matching tests are seldom carried out [15]. In these settings, where emergence of new variants is unpredictable, especially for serotype A FMDV, continuous serological and genetic characterisations of field viruses is needed to understand the cross-reactivity almost of existing vaccines and to trace patterns of viral spread. In this study, the ability of the three existing vaccine strains (A-ERI-1998, A-ETH-06-2000 and A-KEN-05-1980) and four putative candidate vaccine strains (A-EA-2007, A-EA-1984, A-EA-2005 and A-EA-1981) of serotype A FMDV to cross-protect (in-vitro) against the circulating viruses was measured by 2D VNT. The three existing vaccine strains were found to be least cross-reactive (r1-values ≥0.3 observed for only 5.4–46.4% of the sampled viruses) suggesting a poor suitability in the field, unless the low antigenic match can be compensated for by highly potent vaccine formulations [36].